These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 28052289)
1. The Pharmacokinetic Interaction Study between Carvedilol and Bupropion in Rats. Abrudan MB; Muntean DM; Gheldiu AM; Neag MA; Vlase L Pharmacology; 2017; 99(3-4):139-143. PubMed ID: 28052289 [TBL] [Abstract][Full Text] [Related]
2. Inhibitory Effect of Citalopram on the Pharmacokinetics of Carvedilol in Rats and in vitro Models. Abrudan MB; Muntean DM; Popa DS; Gheldiu AM; Neag MA; Vlase L Pharmacology; 2017; 100(5-6):301-307. PubMed ID: 28848215 [TBL] [Abstract][Full Text] [Related]
3. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. Kim MS; Baek IH Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006 [TBL] [Abstract][Full Text] [Related]
4. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats. Lim TH; Cho YA; Choi DH J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083 [TBL] [Abstract][Full Text] [Related]
5. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol. Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. Arsenault WG; Boothe DM; Gordon SG; Miller MW; Chalkley JR; Petrikovics I Am J Vet Res; 2005 Dec; 66(12):2172-6. PubMed ID: 16379664 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015 [TBL] [Abstract][Full Text] [Related]
8. Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study. Kim YH; Choi HY; Noh YH; Lee SH; Lim HS; Kim C; Bae KS Drug Des Devel Ther; 2015; 9():2911-8. PubMed ID: 26089641 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH; Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231 [TBL] [Abstract][Full Text] [Related]
10. Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model. El-Demerdash E; Abdel-Sattar SA; El-Bakly WM; Mohamed EA Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):767-779. PubMed ID: 28012025 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic properties of a new controlled-release formulation of carvedilol. Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228 [TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats. Wang L; Wang S; Chen M; Chen X; Lin Y; Hu X; Huang X; Li X; Hu G Drug Dev Ind Pharm; 2015; 41(10):1661-6. PubMed ID: 25417773 [TBL] [Abstract][Full Text] [Related]
14. Saturable enantioselective first-pass effect for carvedilol after high oral racemate doses in rats. Stahl E; Henke D; Mutschler E; Spahn-Langguth H Arch Pharm (Weinheim); 1993 Mar; 326(3):123-5. PubMed ID: 8097624 [TBL] [Abstract][Full Text] [Related]
15. Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics. Stahl E; Baumgartner U; Henke D; Schölmerich J; Mutschler E; Spahn-Langguth H Chirality; 1993; 5(1):1-7. PubMed ID: 8095396 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. Miki S; Masumura H; Kaifu Y; Yuasa S J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S62-8. PubMed ID: 1721982 [TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. Louis WJ; McNeil JJ; Workman BS; Drummer OH; Conway EL J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S89-93. PubMed ID: 2454376 [TBL] [Abstract][Full Text] [Related]
18. The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. Stout SM; Nielsen J; Bleske BE; Shea M; Brook R; Kerber K; Welage LS J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):373-9. PubMed ID: 20705902 [TBL] [Abstract][Full Text] [Related]